Abcellera and rallybio announce strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases

Vancouver, british columbia & new haven, conn.--( business wire )--abcellera (nasdaq: abcl) and rallybio corporation (nasdaq: rlyb) announced today that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. this multi-year, multi-target collaboration will combine abcellera's antibody discovery engine with rallybio's clinical and commercial expertise in rare diseases to identify optimal clinical candidates and ultimately deliver therapies to patients.
ABCL Ratings Summary
ABCL Quant Ranking